Shares of Sanofi (NASDAQ:SNY – Get Free Report) have been given a consensus recommendation of “Hold” by the twenty-one research firms that are covering the firm, MarketBeat.com reports. Twelve equities research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $53.00.
Several analysts have recently issued reports on SNY shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research report on Tuesday, September 29th. HSBC reiterated a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. Royal Bank Of Canada assumed coverage on Sanofi in a research note on Tuesday, September 8th. They set a “sector perform” rating on the stock. Sanford C. Bernstein restated a “buy” rating on shares of Sanofi in a research report on Monday, August 3rd. Finally, Berenberg Bank restated a “buy” rating on shares of Sanofi in a research report on Monday, October 5th.
View Our Latest Stock Report on SNY
Hedge Funds Weigh In On Sanofi
Sanofi Price Performance
Sanofi stock opened at $48.23 on Wednesday. The company has a market cap of $116.93 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 1.32 and a beta of 0.31. The firm’s fifty day moving average is $42.44 and its 200 day moving average is $44.36. The company has a quick ratio of 0.27, a current ratio of 1.12 and a debt-to-equity ratio of 0.20. Sanofi has a 52-week low of $39.07 and a 52-week high of $52.68.
Sanofi (NASDAQ:SNY – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.56 by $0.48. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The business had revenue of $17.25 billion during the quarter, compared to analyst estimates of $14.30 billion. During the same quarter last year, the business earned $2.91 earnings per share. Sanofi’s quarterly revenue was up 16.2% compared to the same quarter last year. Sell-side analysts forecast that Sanofi will post 5.07 EPS for the current fiscal year.
About Sanofi
Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.
Further Reading
- Five stocks we like better than Sanofi
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
